— BiolineRX (NASDAQ: BLRX) reported third
quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the
loss per share was cents per share, narrower than a loss of 6 cents per share
last year, due to higher share count.
R&D expenses rose 11% to $5.6 million, primarily due to costs associated
with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results
expected by the end of the year.
shares are down 75% so far this year.